VIDEO: Availability of CAR-T therapy still limited

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The availability of CAR T-cells is extremely limited. Even the two of the products are currently commercially available. Both the companies, their ability to produce CAR T-cell is still limited, by various reason, various factors. And so we all end up having waiting lists for patients. They may need CAR T-cells, but we don't have access to a slot, what we call slot for the patient available. And so I think access to CAR T-cell is quite limited at the moment. Both the companies are ramping up their efforts. I think, hopefully, in the next six to 12 months it may end up becoming available as and when we need it, rather than waiting for a slot to become available. Also, there is similar products called Bispecifics that are in the pipeline. Two or three of them are already close to being submitted for FDA approval or already submitted. And they also might help alleviate some of this crunch in getting slots for. So I think this is a very important questions. Availability is an issue. And we all hope that it can get resolved and we can provide CAR T access to patients as and when they need it instead waiting for it.